Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825–33.

Article  PubMed  PubMed Central  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.

Article  CAS  PubMed  Google Scholar 

Hehlmann R. The new ELN recommendations for treating CML. J Clin Med. 2020;9(11):3671.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi N, Takenaka K, Iriyama N, Kirito K, Kawaguchi T, Kimura S, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN). Int J Hematol. 2024;121(1):5–38.

Article  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.3.2025. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed 4 Dec 2024.

Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186–93.

Article  PubMed  PubMed Central  Google Scholar 

Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gambacorti-Passerini C, Chen C, Davis C, Sen GP, Guyan C, Hehlmann R, et al. Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data. Eur J Haematol. 2021;106(1):82–9.

Article  CAS  PubMed  Google Scholar 

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2019;94(1):46–54.

Article  CAS  PubMed  Google Scholar 

Held N, Atallah EL. Real-world management of CML: outcomes and treatment patterns. Curr Hematol Malig Rep. 2023;18(5):167–75.

Article  PubMed  Google Scholar 

Kota VK, Wei D, Yang D, Romdhani H, Latremouille-Viau D, Guérin A, et al. treatment patterns and modifi cations of tyrosine kinase inhibitors (TKI) therapy in earlylines in patients with chronic myeloid leukemia in chronic phase (CML-CP): real-world analysis from a large commercial claims database in the United States (US). Blood. 2023;142:5190.

Article  Google Scholar 

Ota S, Matsukawa T, Yamamoto S, Ito S, Shindo M, Sato K, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95–105.

Article  CAS  PubMed  Google Scholar 

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system. Int J Hematol. 2019;109(4):426–39.

Article  CAS  PubMed  Google Scholar 

Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105(6):792–804.

Article  CAS  PubMed  Google Scholar 

Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022;115(1):33–42.

Article  CAS  PubMed  Google Scholar 

Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, et al. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. Int J Hematol. 2022;116(6):871–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98: 106458.

Article  CAS  PubMed  Google Scholar 

Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031–41.

Article  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minami Y, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib in patients with CML-CP previously treated with ≥ 2 tyrosine kinase inhibitors: 96-week results from the Japanese subgroup analysis of the ASCEMBL study. Int J Hematol. 2024;120(3):305–13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, et al. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Med. 2023;12(3):2990–8.

Article  CAS  PubMed  Google Scholar 

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019;381(24):2315–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novartis Europharm Limited. Scemblix 40 mg film-coated tablets—summary of product characteristics (SmPC). 2022. https://ec.europa.eu/health/documents/community-register/2022/20220825156432/anx_156432_en.pdf. Accessed 31 July 2024.

Novartis Pharmaceuticals Corp. East Hanover: Scemblix [prescribing information]. 2021. https://www.novartis.com/us-en/sites/novartis_us/files/scemblix.pdf. Accessed 31 July 2024.

Pharmaceuticals and Medical Devices Agency. Antineoplastic agents/tyrosine kinase inhibitors (ABL Myristoyl pocket binding inhibitor) asciminib hydrochloride tablets. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/300242_4291077F1027_1_03. Accessed 31 July 2024.

Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885–98.

Article  CAS  PubMed  Google Scholar 

Food and Drug Administration. Highlights of prescribing information. Scemblix tablets for oral use. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Accessed 2 Jan 2025.

Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93(5):624–32.

Article  CAS  PubMed  Google Scholar 

Chuah C, Koh LP, Numbenjapon T, Zang DY, Ong KH, Do YR, et al. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021;114(1):65–78.

Article  CAS